Alpna Seth Sells 2,625 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Alpna Seth sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the transaction, the director directly owned 9,767 shares of the company’s stock, valued at approximately $104,702.24. This represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $10.30 on Friday. Keros Therapeutics, Inc. has a fifty-two week low of $9.79 and a fifty-two week high of $22.55. The company has a market capitalization of $203.84 million, a P/E ratio of -3.42 and a beta of 0.94. The stock has a 50-day simple moving average of $11.33 and a 200-day simple moving average of $15.17.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The firm had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. As a group, analysts forecast that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Financial Management Professionals Inc. purchased a new position in shares of Keros Therapeutics in the 4th quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after purchasing an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Keros Therapeutics in the 4th quarter valued at approximately $212,000. Finally, New York State Common Retirement Fund grew its stake in shares of Keros Therapeutics by 264.1% in the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after purchasing an additional 7,700 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Finally, Wells Fargo & Company reduced their target price on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $20.40.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.